🇺🇸 FDA
Patent

US 10821163

Process for the production of a DNA vaccine for cancer immunotherapy

granted A61KA61K2039/522A61K2039/523

Quick answer

US patent 10821163 (Process for the production of a DNA vaccine for cancer immunotherapy) held by Vaximm AG expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vaximm AG
Grant date
Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/522, A61K2039/523, A61K2039/53, A61K39/0011